- $128.21m
- -$54.56m
Biotech firm Nkarta posts Q2 net loss; cash runway into 2029
Brief: Nkarta Q2 EPS USD -0.54
Nkarta, Inc. expected to post a loss of 38 cents a share - Earnings Preview
Biotech experts want FDA drug reviews based on science, not politics (updated)
Biotech experts want FDA drug reviews based on science, not politics
Nkarta Q1 net loss narrows; cash seen funding to 2029
Brief: Nkarta Q1 EPS USD -0.37
Brief: Nkarta Announces FDA Agreement On Outpatient Dosing Of Nkx019 In Autoimmune Disease, Expanding Access To Community Rheumatology Centers
Nkarta Q4 net loss widens
Brief: Nkarta Reports Fourth Quarter And Full Year 2025 Financial Results And Corporate Highlights
Brief: Nkarta Q4 EPS USD -0.37
Nkarta Q3 net loss $21.7 mln
Brief: Nkarta Q3 EPS USD -0.29
Nkarta Inc reports results for the quarter ended June 30 - Earnings Summary
Nkarta Inc expected to post a loss of 35 cents a share - Earnings Preview
Nkarta Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Nkarta Q1 Net Income USD -31.983 Million
Nkarta Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: Nkarta Inc To Reduce Workforce By 34%, Impacting 53 Positions - SEC Filing